Journal
JMIR MHEALTH AND UHEALTH
Volume 11, Issue 1, Pages -Publisher
JMIR PUBLICATIONS, INC
DOI: 10.2196/43675
Keywords
mobile health; mHealth; smartphone; smartphone app; cardiovascular disease; sodium; salt; blood pressure; technology; reduced-sodium salt; mobile phone
Ask authors/readers for more resources
The study aimed to determine whether a 12-week intervention with a sodium-reduction package comprising the SaltSwitch smartphone app and reduced-sodium salts could reduce urinary sodium excretion in adults with high blood pressure. However, the study found no evidence that dietary sodium intake was reduced in adults with high blood pressure. This may be due to lower engagement with the trial intervention package by participants.
Background: Even modest reductions in blood pressure (BP) can have an important impact on population-level morbidity and mortality from cardiovascular disease. There are 2 promising approaches: the SaltSwitch smartphone app, which enables users to scan the bar code of a packaged food using their smartphone camera and receive an immediate, interpretive traffic light nutrition label on-screen alongside a list of healthier, lower-salt options in the same food category; and reduced-sodium salts (RSSs), which are an alternative to regular table salt that are lower in sodium and higher in potassium but have a similar mouthfeel, taste, and flavor. Objective: Our aim was to determine whether a 12-week intervention with a sodium-reduction package comprising the SaltSwitch smartphone app and an RSS could reduce urinary sodium excretion in adults with high BP.Conclusions: In this randomized controlled trial of a salt-reduction package, we found no evidence that dietary sodium intake was reduced in adults with high BP. These negative findings may be owing to lower-than-anticipated engagement with the trial intervention package. However, implementation and COVID-19-related challenges meant that the trial was underpowered, and it is possible that a real effect may have been missed.Trial Registration: Australian New Zealand Clinical Trials Registry ACTRN12619000352101; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377044 and Universal Trial U1111-1225-4471
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available